인도의 자가 혈당 측정 기기 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the India self-Monitoring blood glucose devices market size was valued at USD 230.67 million in 2025 and estimated to grow from USD 243.77 million in 2026 to reach USD 321.29 million by 2031, at a CAGR of 5.68% during the forecast period (2026-2031).

This report is Segmented by Component (Glucometer Devices, Test Strips, and Lancets & Lancing Devices), Technology (Electrochemical Biosensors, Photometric, and More), End User (Home-Care Patients, Hospitals, and More), Distribution Channel (Offline Retail Pharmacies, E-Pharmacies & Direct-To-Consumer, and More). The Market Forecasts are Provided in Terms of Value (USD).

India Self-Monitoring Blood Glucose Devices Market Trends and Insights

Rising Diabetes Prevalence & Earlier Onset

India's 77 million adult Type 2 patient base, alongside 25 million prediabetic individuals, has intensified demand for self-testing devices. Earlier onset among professionals aged 25-40 pushes lifetime monitoring volumes higher and favors connected meters that fit digital lifestyles. The India Self-Monitoring Blood Glucose Devices market consequently records rising repeat purchases of strips and an uptick in premium device upgrades.

Government Screening & Subsidy Programmes

Nationwide screening now spans more than 700 districts, embedding glucose checks in public primary care. Tamil Nadu alone screened 2.5 million residents in 2024, stimulating downstream retail sales of meters and consumables. Partial reimbursements under CGHS and ESIC cover meters but exclude strips, sustaining recurring revenue potential for suppliers while constraining adoption among low-income groups.

High Recurring Cost of Consumables

Monthly strip expenses often exceed the one-time meter outlay, leading to reduced testing frequency among price-sensitive users. Limited private-insurance coverage and minimal public reimbursements exacerbate the affordability gap.

Other drivers and restraints analyzed in the detailed report include:

1. Digital-Health Integration with Glucometers
2. E-Pharmacy Subscription Penetration (Tier-2/3)
3. Limited Insurance / Reimbursement Coverage

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Test strips retained 50.02% ownership of India Self-Monitoring Blood Glucose Devices market share in 2025, highlighting the consumable-centric revenue architecture. Glucometer devices, buoyed by replacement cycles and digital add-ons, are pacing at an 10.74% CAGR. Lancets and lancing devices, though smaller, follow a predictable volume trajectory. BeatO's USB-C Curv launch exemplifies design upgrades aimed at younger, tech-friendly diabetics. SRM Institute's non-invasive prototype, if commercialized, could compress strip demand and reshape the India Self-Monitoring Blood Glucose Devices market.

Electrochemical strips account for the bulk of manufacturing under India's PLI scheme, trimming landed costs by 10-15% and enabling local brands to widen distribution beyond tier-1 cities.

Electrochemical biosensors claimed 76.10% of 2025 revenues, supported by mature supply chains and validated accuracy. Photometric platforms occupy niche institutional demand. Smartphone-integrated dongles, rising at 15.28% CAGR, capitalize on India's 750 million internet-connected handsets. Continuous strip-free cassettes cater to users seeking lower lifetime spend but require higher upfront cash outlay. CDSCO approval processes promote safety yet elongate time-to-market for novel platforms, dictating the pace at which the India Self-Monitoring Blood Glucose Devices market absorbs next-gen formats.

Complete Report Scope:

• By Component
  • Glucometer Devices
  • Test Strips
  • Lancets & Lancing Devices
• By Technology
  • Electrochemical Biosensors
  • Photometric (Optical)
  • Continuous Strip-Free (e.g., cassette)
  • Smartphone-integrated Dongles
• By End User
  • Home-care Patients
  • Hospitals
  • Clinics & Diagnostic Labs
  • Pharmacies & Wellness Stores
• By Distribution Channel
  • Offline Retail Pharmacies
  • Hospital-based Procurement
  • e-Pharmacies & Direct-to-Consumer

List of Companies Covered in this Report:

1. Abbott Laboratories
2. AgaMatrix
3. Arkray
4. Ascensia
5. BeatO (HealthArx)
6. Bionime
7. Morepen
8. Dr. Trust (Nureca)
9. ForaCare
10. i-SENS Inc.
11. Lifescan
12. Menarini Diagnostics
13. Nova Biomedical
14. Roche
15. Samajkalyan Pharma (Accurex)
16. Sinocare
17. Truworth Health
18. Ypsomed

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Diabetes Prevalence & Earlier Onset
  • 4.2.2 Government Screening & Subsidy Programmes
  • 4.2.3 Higher Disposable Income & Lifestyle Awareness
  • 4.2.4 Digital-Health Integration with Glucometers
  • 4.2.5 E-Pharmacy Subscription Penetration (Tier-2/3)
  • 4.2.6 Localised Strip Manufacturing Under PLI Scheme
• 4.3 Market Restraints
  • 4.3.1 High Recurring Cost of Consumables
  • 4.3.2 Limited Insurance / Reimbursement Coverage
  • 4.3.3 Counterfeit & Grey-Market Strips Undermine Trust
  • 4.3.4 Data-Privacy Risks in App-Linked Devices
• 4.4 Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Bargaining Power of Suppliers
  • 4.7.2 Bargaining Power of Consumers
  • 4.7.3 Threat of New Entrants
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Component
  • 5.1.1 Glucometer Devices
  • 5.1.2 Test Strips
  • 5.1.3 Lancets & Lancing Devices
• 5.2 By Technology
  • 5.2.1 Electrochemical Biosensors
  • 5.2.2 Photometric (Optical)
  • 5.2.3 Continuous Strip-Free (e.g., cassette)
  • 5.2.4 Smartphone-integrated Dongles
• 5.3 By End User
  • 5.3.1 Home-care Patients
  • 5.3.2 Hospitals
  • 5.3.3 Clinics & Diagnostic Labs
  • 5.3.4 Pharmacies & Wellness Stores
• 5.4 By Distribution Channel
  • 5.4.1 Offline Retail Pharmacies
  • 5.4.2 Hospital-based Procurement
  • 5.4.3 e-Pharmacies & Direct-to-Consumer

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Business Segments, Financials, Headcount, Key Information, Market Rank, Market Share, Products and Services, and analysis of Recent Developments)
  • 6.3.1 Abbott Diabetes Care
  • 6.3.2 AgaMatrix
  • 6.3.3 Arkray Inc.
  • 6.3.4 Ascensia Diabetes Care
  • 6.3.5 BeatO (HealthArx)
  • 6.3.6 Bionime Corporation
  • 6.3.7 Dr. Morepen
  • 6.3.8 Dr. Trust (Nureca)
  • 6.3.9 ForaCare
  • 6.3.10 i-SENS Inc.
  • 6.3.11 LifeScan
  • 6.3.12 Menarini Diagnostics
  • 6.3.13 Nova Biomedical
  • 6.3.14 Roche Diabetes Care
  • 6.3.15 Samajkalyan Pharma (Accurex)
  • 6.3.16 Sinocare
  • 6.3.17 Truworth Health
  • 6.3.18 Ypsomed

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment